<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The outcome of continued EPO therapy was studied in 18 responding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>The EPO dose was reduced in a stepwise fashion to find the lowest possible maintenance dose </plain></SENT>
<SENT sid="2" pm="."><plain>Relapses of <z:hpo ids='HP_0001903'>anemia</z:hpo> were associated with either progressive disease or reduction of the administered EPO dose </plain></SENT>
<SENT sid="3" pm="."><plain>In the latter group second responses to renewed EPO therapy were readily achieved </plain></SENT>
<SENT sid="4" pm="."><plain>Long-term responses were seen in about a third of the patients </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, it seems safe to reduce the EPO dose among responding patients </plain></SENT>
<SENT sid="6" pm="."><plain>This approach may have advantages both from a medical and a socio-economic perspective </plain></SENT>
</text></document>